Evidence map›Paper›PMID 34410992›Full record

ArticleIn vivo (Athens, Greece)

Nine Cases of SARS-CoV-2-PCR-positive Samples Showed No Increase of Antibodies Against SARS-CoV-2.

Takao Kitagawa, Masanobu Kobayashi, Tohru Ohta, Masaru Terasaki, Yoko Tsukamoto, Rie Takai, Reika Ishizumi, Osamu Uehara, Koji Nakagawa, Kozo Akino and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Takao KitagawaAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Masanobu KobayashiAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Tohru OhtaAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Masaru TerasakiAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Yoko TsukamotoSchool of Nursing and Social Services, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Rie TakaiAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Reika IshizumiSchool of Nursing and Social Services, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Osamu UeharaAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Koji NakagawaAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Kozo AkinoAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Masahiro AsakaAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan.
Yasuhiro KuramitsuAdvanced Research Promotion Center, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Japan; climates@hoku-iryo-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been affecting Hokkaido, Japan since late February 2020 until present. The aim of this study was to report the relationship between anti-SARS-CoV-2 antibody-positive and SARS-CoV-2 PCR-positive cases by analyzing anti-SARS-CoV-2 antibodies (IgG and total-Ig). PATIENTS AND

methodsSerum samples were collected from care workers and nurses in two nursing homes and two hospitals which underwent virus outbreak. All people were confirmed to be SARS-CoV-2-positive by RT-qPCR and their sera was analyzed for anti-SARS-CoV-2 antibodies (IgG and total-Ig).

resultsAlthough 34 out of 43 samples (79.1%) showed enough amount of anti-SARS-CoV-2 antibodies, 9 RT-qPCR -positive samples (20.9%) showed absence of anti-SARS-CoV-2 antibodies in their sera.

conclusionThe results that 20.9% of RT-qPCR-positive samples with SARS-CoV-2 showed absence of anti-SARS-CoV-2 antibodies provides a possibility that the innate immune reaction could eliminate the virus without activating adaptive immune reaction.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralHumansImmunoglobulin GPolymerase Chain ReactionAntibodies, ViralImmunoglobulin GantibodiesCOVID-19innate immunitySARS-Cov-2

Identifiers

PMID34410992
PMCPMC8408738

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.